News
Galapagos signs deal with Scipher for IBD drug development
Belgium-based biotech Galapagos has signed a collaboration deal with Scipher Medicine to advance novel drug targets for the treatment of inflammatory bowel disease (IBD).
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Belgium-based biotech Galapagos has signed a collaboration deal with Scipher Medicine to advance novel drug targets for the treatment of inflammatory bowel disease (IBD).